BVS

Bioventus Inc. (BVS)

Healthcare • Medical Devices

StockNasdaqGSUnited StatesUS09075A1088

10.87 USD +0.09% today Updated 13 Nov 2026 15:24

Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by Bioventus Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.

Price history

Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.

All time

Updated 13 Nov 2026 15:24. Information, not advice. Showing the last 12 months. Create a free account to see the whole history

Results

Next results 09 Mar 2027 in 116 days · 08:00 · estimate 0.24

Last results 0.17 vs 0.16 estimated 02 Nov 2026 · Beat +6.3%

Beat the estimate 11 of 12 0 missed · 1 in line

Average surprise +118.6% reported against the estimate, last 12 quarters

Earnings per share: estimate and reported

Estimate Reported: beat Reported: miss In line

Quarterly results

Date	EPS estimate	EPS reported	Surprise	Result
09 Mar 2027 08:00	0.24	—	—	Upcoming
02 Nov 2026 16:00	0.16	0.17	+6.3%	Beat
05 Aug 2026 07:00	0.22	0.22	+0.9%	In line
06 May 2026 07:00	0.07	0.15	+120.6%	Beat
05 Mar 2026 07:00	0.22	0.24	+10.8%	Beat
04 Nov 2025 07:00	0.12	0.15	+30.4%	Beat
06 Aug 2025 07:00	0.20	0.21	+6.8%	Beat
06 May 2025 07:00	0.02	0.08	+250.6%	Beat
11 Mar 2025 07:00	0.08	0.15	+76.5%	Beat
05 Nov 2024 07:00	0.02	0.06	+296.8%	Beat
06 Aug 2024 07:00	0.07	0.19	+191.1%	Beat
07 May 2024 07:00	-0.07	0.07	+206.9%	Beat
12 Mar 2024 07:00	0.02	0.07	+225.6%	Beat
07 Nov 2023 07:00	-0.02	0.05	+340.2%	Beat
08 Aug 2023 08:00	—	0.14	+3,755.4%	Beat
16 May 2023 16:00	-0.16	-0.26	-59.2%	Miss
31 Mar 2023 07:00	0.05	-0.06	-226.2%	Miss
08 Nov 2022 07:00	0.12	0.08	-34.5%	Miss
11 Aug 2022 07:00	0.16	0.10	-36.3%	Miss
10 May 2022 07:00	0.05	0.04	-15.2%	Miss
10 Mar 2022 07:00	0.18	0.26	+47.5%	Beat
09 Nov 2021 07:00	0.15	0.25	+66.7%	Beat
10 Aug 2021 16:00	0.14	0.16	+16.4%	Beat
12 May 2021 16:00	0.10	0.15	+57.9%	Beat
25 Mar 2021 16:00	0.23	2.32	+908.7%	Beat

Annual results · USD

Year	Revenue	Change	Net income	Net margin	EPS	EPS change	Free cash flow
2025	568.1M	-0.9%	22.7M	4.0%	0.33	+163.5%	72.1M
2024	573.3M	+11.9%	-36.1M	-6.3%	-0.52	+79.1%	37.8M
2023	512.3M	+0.0%	-156.2M	-30.5%	-2.49	+3.9%	8M
2022	512.1M	—	-158.7M	-31.0%	-2.59	—	-15M
2021	—	—	—	—	—	—	—

Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.

Prices by day, week and month

Day Week Month

Price history in USD, by week
Period	Opening price	High	Low	Closing price	Change	Volume
09 Nov 2026 – 13 Nov 2026 In progress	10.95	11.27	10.55	10.87	+2.45%	2,419,635
02 Nov 2026 – 06 Nov 2026	13.52	13.73	10.09	10.61	-20.38%	5,840,900
26 Oct 2026 – 30 Oct 2026	15.21	15.33	13.32	13.33	-10.93%	2,540,000
19 Oct 2026 – 23 Oct 2026	13.27	15.10	13.15	14.96	+12.48%	2,221,900
12 Oct 2026 – 16 Oct 2026	13.07	14.00	12.99	13.30	+1.80%	1,747,200
05 Oct 2026 – 09 Oct 2026	13.13	13.62	12.52	13.07	-0.50%	1,676,400
28 Sep 2026 – 02 Oct 2026	13.81	14.15	13.02	13.13	-4.92%	2,370,600
21 Sep 2026 – 25 Sep 2026	13.04	13.94	12.76	13.81	+6.97%	2,018,800
14 Sep 2026 – 18 Sep 2026	13.00	13.33	12.34	12.91	-0.54%	2,586,500
08 Sep 2026 – 11 Sep 2026	14.04	14.08	12.92	12.98	-7.75%	1,864,500
00 Mon 0000	157.29	236.48	315.67	394.86	+0.00%	000,000
00 Mon 0000	553.24	632.43	711.62	790.81	+0.00%	000,000
00 Mon 0000	49.19	128.38	207.57	286.76	+0.00%	000,000
253 older periods: create a free account to see the whole history

Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.

News

What Bioventus Shareholders Got Right (opens in a new tab) Simply Wall St. · 07 Nov 2026 23:10
Bioventus Inc. 2026 Q3 - Results - Earnings Call Presentation (opens in a new tab) SeekingAlpha · 05 Nov 2026 18:16
Bioventus (BVS) Stock Price Slides After Q3 Results Cut Revenue Outlook (opens in a new tab) Simply Wall St. · 04 Nov 2026 04:37
Canaccord Genuity Maintains Buy on Bioventus, Lowers Price Target to $18 (opens in a new tab) Benzinga · 03 Nov 2026 09:25
Adeia Posts Downbeat Q3 Earnings, Joins Bioventus, Apple And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session (opens in a new tab) Benzinga · 03 Nov 2026 09:02
Bioventus Inc (BVS) Q3 2026 Earnings Call Highlights: Solid Pain and Ultrasonics Growth Offset ... (opens in a new tab) GuruFocus.com · 03 Nov 2026 07:04
Bioventus (BVS) Q3 2026 Earnings Call Transcript (opens in a new tab) Motley Fool · 03 Nov 2026 04:28
Bioventus Inc. (BVS) Q3 2026 Earnings Call Transcript (opens in a new tab) SeekingAlpha · 03 Nov 2026 01:28
Bioventus Q3 Earnings Call Highlights (opens in a new tab) MarketBeat · 02 Nov 2026 23:13
Bioventus (NASDAQ:BVS) Falls After Q3 Revenue Miss and Below-Consensus Sales Guidance Despite EPS Beat (opens in a new tab) ChartMill · 02 Nov 2026 23:08
Bioventus: Q3 Earnings Snapshot (opens in a new tab) Associated Press · 02 Nov 2026 23:01
Bioventus (BVS) Matches Q3 Earnings Estimates (opens in a new tab) Zacks · 02 Nov 2026 21:55
Bioventus Reports Third Quarter Financial Results (opens in a new tab) 02 Nov 2026 21:05
Bioventus Q3 2026 Earnings Call Transcript (opens in a new tab) Benzinga · 02 Nov 2026 18:25
Bioventus Affirms FY2026 Adj EPS Guidance of $0.75-$0.79 vs $0.78 Est; Lowers FY2026 Sales Guidance from $600.000M-$610.000M to $590.000M-$595.000M vs $604.782M Est (opens in a new tab) Benzinga · 02 Nov 2026 17:19

Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.

Key data

Previous close: 10.86 USD
Market cap: 749.3M
Exchange: NasdaqGS
Country: United States
Sector: Healthcare
Industry: Medical Devices
Currency: USD

Dividends

No dividends on record.

Why this score

How the score is made up
Part of the score	Points	Why
Business growth Yearly growth of revenue and of earnings per share.	5.9 / 25	Revenue growth of 3.5% a year
Quality Return on equity, net margin and how stable the margins are.	13.0 / 25	ROE of 26%
Financial strength Net debt against operating earnings, interest cover and free cash flow.	11.6 / 20	Net debt is 2.7× EBITDA Free cash flow yield of 7.5%
Valuation Free cash flow yield and the P/E against its sector.	15.0 / 15	P/E 13.4 against 30.6 for its sector
Analysts How far the analysts' average target is from today's price.	10.0 / 10	Analysts' target is +53% from the price

Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 95% of the figures (grade A).

Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio. How the score works

Figures

Valuation
Figure	Value	Reading	Sector median
P/E (trailing)	13.41×	Good	30.56×
P/E (forward)	12.23×	Good	14.16×
Price / book	3.09×	Weak	3.5×
Price / sales	1.27×	Good	3.33×
EV / EBITDA	12.98×	Fair	11.19×
Free cash flow yield	7.5%	Good	2.1%

Quality
Figure	Value	Reading	Sector median
Gross margin	68.7%	Good	54.9%
Operating margin	10.1%	Fair	5.8%
Net margin	9.8%	Fair	1.2%
Return on equity	25.8%	Good	4.4%
Return on assets	5.4%	Fair	2.7%

Growth
Figure	Value	Reading	Sector median
Revenue growth / year	3.5%	Fair	10.1%

Financial health
Figure	Value	Reading	Sector median
Debt / equity	0.84×	Fair	0.4×
Net debt / EBITDA	2.72×	Fair	1.46×
Interest cover	2.13×	Weak	2.17×
Current ratio	1.68×	Good	2.64×

Dividends
Figure	Value	Reading	Sector median
Payout of earnings	0%	Weak	0%

The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.

Similar shares

Follow BVS and get alerts

Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.

Start for free Log in